For the quarter ending 2025-09-30, EWTX made $53,547K in revenue. -$40,169K in net income. Net profit margin of -75.02%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 37,480 | 33,558 | ||
| General and administrative | 9,378 | 9,052 | ||
| Total operating expenses | 46,858 | 42,610 | ||
| Loss from operations | -46,858 | -42,610 | ||
| Interest income | 6,192 | 6,495 | ||
| Total other income | 6,192 | 6,495 | ||
| Net loss | -40,666 | -36,115 | ||
| Unrealized gain on available-for-sale securities | 497 | -197 | ||
| Total comprehensive loss | -40,169 | -36,312 | ||
| Earnings per share, basic | -0.39 | -0.34 | ||
| Earnings per share, diluted | -0.39 | -0.34 | ||
| Weighted average number of shares outstanding, basic | 105,492,779 | 104,940,493 | ||
| Weighted average number of shares outstanding, diluted | 105,492,779 | 104,940,493 | ||
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)